Identification of EGFR-TKIs Sensitivity or Resistance Markers in the Tumor May Help in Optimal Patient Selection
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Istituto Clinico Humanitas.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Istituto Clinico Humanitas
Information provided by:
Istituto Clinico Humanitas
ClinicalTrials.gov Identifier:
NCT00831454
First received: January 28, 2009
Last updated: September 1, 2010
Last verified: September 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.
Condition |
---|
Non-Small-Cell Lung Cancer |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
Official Title: | RELATIONSHIP OF POLYMORPHISMS AND MUTATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND TYROSINE KINASE INHIBITORS RESPONSIVENESS IN NON-SMALL-CELL LUNG CANCER PATIENT |
Resource links provided by NLM:
Further study details as provided by Istituto Clinico Humanitas:
Primary Outcome Measures:
- to evaluate the presence of EGFR- and AKT-DNA polymorphisms. [ Time Frame: At the end of enrollment ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- to correlate the biological characteristics with clinical characteristics and survival data of patients. [ Time Frame: At the end of enrollment ] [ Designated as safety issue: No ]
Estimated Enrollment: | 100 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | October 2008 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Study Population
NON-SMALL-CELL LUNG CANCER patients treated with EGFR-TKIs
Criteria
Inclusion Criteria:
- Availability of tumor tissue or blood samples.
Contacts and Locations
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 18, 2012
No publications provided
Responsible Party: | Armando Santoro, MD, Istituto Clinico Humanitas |
ClinicalTrials.gov Identifier: | NCT00831454 History of Changes |
Other Study ID Numbers: | ONC/OSS-02/2008 |
Study First Received: | January 28, 2009 |
Last Updated: | September 1, 2010 |
Health Authority: | Italy: Ministry of Health |
Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on October 18, 2012